Checkpoint Therapeutics Q4 2020 Earnings Report
Key Takeaways
Checkpoint Therapeutics announced its full-year 2020 financial results, highlighting the progress of cosibelimab in metastatic cutaneous squamous cell carcinoma (mCSCC) and positive interim data from its Phase 1 program. The company's registration-enabling study in mCSCC is approximately 90% enrolled, with full enrollment anticipated shortly, and top-line results expected in the second half of 2021.
Cosibelimab registration path in mCSCC is solidifying.
Positive interim data from pivotal Phase 1 program was announced.
Registration-enabling study in mCSCC is approximately 90% enrolled, with full enrollment anticipated shortly.
Full top-line results are expected in the second half of 2021.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
Checkpoint Therapeutics anticipates a transformative year, focusing on progress towards its first BLA submission with the FDA for cosibelimab in 2022.